Xilio Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
XLO Nasdaq 2836 xiliotx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Xilio Therapeutics, Inc.

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results - May 8th, 2025 11:30 am
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - May 2nd, 2025 8:30 pm
Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting - Apr 23rd, 2025 8:30 pm
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 4th, 2025 8:30 pm
Xilio Therapeutics, Inc. (XLO) Reports Q4 Loss, Lags Revenue Estimates - Mar 11th, 2025 12:45 pm
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results - Mar 11th, 2025 11:30 am
Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - Feb 24th, 2025 9:30 pm
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs - Feb 14th, 2025 1:03 pm
AbbVie and Xilio to collaborate on antibody-based immunotherapies - Feb 13th, 2025 9:17 am
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday? - Feb 12th, 2025 3:44 pm
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs - Feb 12th, 2025 12:35 pm
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies - Feb 12th, 2025 12:33 pm
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - Jan 21st, 2025 10:05 pm
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI - Dec 19th, 2024 12:30 pm
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - Dec 16th, 2024 12:30 pm
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright - Dec 9th, 2024 2:55 pm
Here's Why We're Not Too Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation - Dec 6th, 2024 3:46 pm
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors - Nov 7th, 2024 2:15 pm
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results - Nov 7th, 2024 2:05 pm
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - Oct 30th, 2024 1:01 pm